BioCentury
ARTICLE | Finance

Ablynx juggling

Ablynx faces choices after breakup with Pfizer and Phase II trial miss

November 14, 2011 8:00 AM UTC

A third Nanobody deal with Merck Serono S.A. wasn't a charm for Ablynx N.V. (Euronext:ABLX), whose shares have been weighed down by disappointments involving two Phase II programs in as many weeks.

Last week, the company said it would discontinue development of ALX-0081 to treat acute coronary syndrome after it missed the primary endpoint in a Phase II trial in high-risk patients with ACS undergoing percutaneous coronary intervention (PCI) (see B15). ...